Abogen Biosciences is a clinical-stage biotechnology company developing mRNA drugs and vaccines for infectious diseases, oncology and autoimmune conditions.
Abogen Biosciences reports positive preliminary first-in-human data for ABO2203, an mRNA-encoded CD3xCD19 T-cell engager, in relapsed/refractory B-NHL. The company presents the data in an oral session at AACR 2026, and ABO2203 is also studied in autoimmune diseases.
Abogen Biosciences receives dual IND approvals from China’s NMPA and the US FDA for ABO2102, its KRAS mRNA cancer vaccine. The company says the vaccine demonstrates anti-tumor activity, and the approvals expand its oncology pipeline.
Abogen Biosciences secures IND approval in March 2025 for its mRNA shingles vaccine. The vaccine targets varicella-zoster virus (VZV) and uses the company’s proprietary base-modification and structure-design platform; it is part of Abogen’s diversified infectious-disease pipeline.
Abogen receives an IND for its lyophilized mRNA RSV vaccine, which uses base modification and a self-developed LNP. The vaccine has large-scale Phase 3 validation, China IP, and more than two years of stability at 2–8°C.
